Clinical Trial Update: Baricitinib for Refractory Takayasu Arteritis [Phase 2]

View source ↗

Summary

Baricitinib was evaluated in a Phase 2 trial for refractory Takayasu arteritis and has completed. The sponsor listed is Liu Tian.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Takayasu Arteritis

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Liu Tian | Conditions: Takayasu Arteritis | Phase 2 | Status: COMPLETED